FDA approves renaming Rybelsus tablets to Ozempic tablets

On January 30, 2026, the FDA approved a labeling update that renames the reformulated oral semaglutide product Rybelsus as Ozempic tablets ^[1][2]. The tablets keep the same three strengths — 1.5 mg, 4 mg and 9 mg — and the same approved uses in adults with type 2 diabetes: improving blood sugar control and reducing the risk of major cardiovascular events in people at high risk ^[2][4].

The product involved is the "R2" formulation of oral semaglutide, first approved on December 9, 2024 ^[1]. It replaced the original Rybelsus tablets of 3 mg, 7 mg and 14 mg, known as the R1 formulation, which are still listed under the Rybelsus name ^[1][2]. Pharmacy Times reports that the R2 tablets deliver about 25% greater semaglutide exposure than R1, so the smaller numbers on the label do not mean a weaker dose: 1.5 mg of the R2 tablet is bioequivalent to 3 mg of R1, 4 mg to 7 mg, and 9 mg to 14 mg ^[3]. The FDA label states that Rybelsus and Ozempic tablets are "not substitutable on a mg-to-mg basis" ^[2].

Novo Nordisk made the change to "reduce patient confusion and unify all of its GLP-1 products for T2D under 1 brand," Pharmacy Times reported ^[3]. Ozempic has been an FDA-approved brand since December 5, 2017, when the once-weekly injection was cleared for type 2 diabetes ^[4]. The name now covers both a weekly injection and a once-daily tablet ^[4].

Daily use instructions for the tablet are unchanged ^[2]. The starting dose is 1.5 mg once daily for 30 days, then 4 mg once daily; on day 61 or later, the dose can go to 9 mg if more blood sugar control is needed ^[2]. According to the label, the first 30 days at 1.5 mg is not effective for glycemic control ^[2]. The tablet is taken once daily in the morning on an empty stomach with no more than 4 ounces of plain water, swallowed whole, and at least 30 minutes must pass before food, other drinks or other oral medicines ^[2][3].

The safety information did not change with the name. Ozempic tablets and Rybelsus carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 ^[2][3]. Common side effects reported in 5% or more of patients include nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation ^[1][2]. Warnings also cover acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, gallbladder disease and pulmonary aspiration during general anesthesia or deep sedation ^[2].

Oral semaglutide for weight management is a separate product. The FDA approved Wegovy tablets on December 22, 2025, in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, for weight reduction and cardiovascular risk reduction in adults with obesity or overweight ^[1][4]. Pharmacy Times notes that Ozempic tablets are approved only for blood sugar control and cardiovascular risk reduction in type 2 diabetes, while the Wegovy pill is approved as an adjunct to diet and exercise for chronic weight management ^[3].

Why it matters for patients

If a prescription label changes from Rybelsus to Ozempic tablets, the medicine inside is the same molecule, semaglutide, at the same strength ^[1][3]. Pharmacy Times advises that patients making the switch be reassured that "a lower dose number does not mean a weaker medication" ^[3]. Because the R1 and R2 tablets are not interchangeable milligram for milligram, changing between them without a prescriber's guidance could change how much drug a person actually gets ^[2][3].

The one-word difference between Ozempic injection and Ozempic tablets matters day to day. The injection is given once weekly, at any time of day, with or without meals, while the tablets are taken once daily on an empty stomach ^[4]. Whether the rename changes insurance coverage, copays or prior authorization requirements has not been reported.

What happens next

Novo Nordisk introduced the Ozempic pill with US availability planned for the second quarter of 2026 ^[6][9], and Pharmacy Times reported a nationwide US launch under the Ozempic brand as of May 4, 2026 ^[3]. What will happen to the original Rybelsus 3 mg, 7 mg and 14 mg tablets in the US has not been disclosed; the FDA label updated on January 30, 2026 covers both Rybelsus and Ozempic tablets ^[2].